Clinical trial of 5'-DFUR against various malignant tumors

5'-DFUR was administered orally to 18 patients with various malignant tumors at a daily dose of 800-1200 mg to evaluate its clinical efficacy and side effects. Out of 17 evaluable cases, PR was observed in one larynx cancer case and three breast cancer cases, with an efficacy rate of 23.5%. Side effects was observed in only one case. These were digestive symptoms which were alleviated by reduction of the dosage. No other severe side effect was observed. These results suggest that 5'-DFUR has potential as a useful oral anticancer agent.